IQVIA Announces Pricing of Offering of Senior Notes
February 17 2021 - 4:27PM
Business Wire
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV) today announced that
its wholly owned subsidiary, IQVIA Inc. (the “Issuer”), priced an
offering of €1,450,000,000 in aggregate principal amount of senior
notes, consisting of €550,000,000 in aggregate principal amount of
senior notes due 2026 (the “2026 Notes”) and €900,000,000 in
aggregate principal amount of senior notes due 2029 (the “2029
Notes” and, together with the 2026 Notes, the “Notes”). The
proceeds from the Notes offering will be used to redeem all of the
Issuer’s outstanding 3.250% senior notes due 2025, including the
payment of premiums in respect thereof, and to pay fees and
expenses related to the Notes offering.
The 2026 Notes will bear interest at a rate of 1.750% per annum
and will pay interest semi-annually in arrears on March 15 and
September 15 of each year, beginning on September 15, 2021. The
2026 Notes will mature on March 15, 2026, unless earlier
repurchased or redeemed in accordance with their terms. The 2029
Notes will bear interest at a rate of 2.250% per annum and will pay
interest semi-annually in arrears on March 15 and September 15 of
each year, beginning on September 15, 2021. The 2029 Notes will
mature on March 15, 2029, unless earlier repurchased or redeemed in
accordance with their terms. The issuance of the Notes is expected
to occur on or about March 3, 2021, subject to the satisfaction of
customary closing conditions.
Certain statements in this press release are forward-looking
statements. These statements involve a number of risks,
uncertainties and other factors, including the failure to
consummate the Notes offering and potential changes in market
conditions that could cause actual results to differ
materially.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy the Notes, nor shall there be any
offer, solicitation or sale of the Notes in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful. The Notes to be offered have not been, and will not be,
registered under the Securities Act of 1933, as amended (the
“Securities Act”), or the securities laws of any other jurisdiction
and may not be offered or sold in the United States absent
registration or an applicable exemption from the registration
requirements of the Securities Act. The Notes are being offered
only to persons reasonably believed to be qualified institutional
buyers in the United States in reliance on Rule 144A under the
Securities Act and outside the United States only to non-U.S.
investors pursuant to Regulation S under the Securities Act. Any
offer of the Notes will be made only by means of a private offering
memorandum.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 70,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures.
IQVIAFIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210217005996/en/
IQVIA Holdings Inc. Investor Relations: Andrew Markwick,
973-257-7144 andrew.markwick@iqvia.com
or
Media Relations: Tor Constantino, 484-567-6732
tor.constantino@iqvia.com
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024